IMMUNITYBIO, INC. Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Compensation
IMMUNITYBIO, INC. (IBRX) had Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Compensation of $3.26 million as of 2023-12-31, per its 10-K filed 2024-03-19.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Gross › Deferred Tax Assets, Tax Deferred Expense
us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation · last filed 2024-03-19
- 2023-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Compensation $3.26M.
- 2022-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Compensation $3.40M.
- 2021-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Compensation $2.52M.
- 2020-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Compensation $1.53M; Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Compensation as first filed $762.00K.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Compensation | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Compensation as first filed |
|---|---|---|
| 2023-12-31 | $3.26M 10-K · filed 2024-03-19 | |
| 2022-12-31 | $3.40M 10-K · filed 2024-03-19 | |
| 2021-12-31 | $2.52M 10-K · filed 2023-03-01 | |
| 2020-12-31 | $1.53M 10-K · filed 2022-03-01 | $762.00K 10-K · filed 2021-03-04 |
| 2019-12-31 | $1.39M 8-K/A · filed 2021-04-22 | $775.00K 10-K · filed 2020-03-25 |
| 2018-12-31 | $795.00K 10-K · filed 2020-03-25 | |
| 2017-12-31 | $682.00K 10-K · filed 2019-03-13 | |
| 2016-12-31 | $808.00K 10-K · filed 2018-03-12 | |
| 2015-12-31 | $572.00K 10-K · filed 2017-03-15 | |
| 2014-12-31 | $75.00K 10-K · filed 2016-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |